Barbara Érsek

Introduction Allogeneic hematopoietic stem cell transplantation (aHSCT) is a potentially curative therapy for various malignant and nonmalignant diseases affecting the hematopoietic system. Upon aHSCT, a side effect of the therapy, acute graft versus host disease (aGvHD) may develop, characterized by high morbidity and mortality [1].

1. Introduction Over recent decades, stromal cells of the TME have emerged as some of the crucial determinants of tumor progression and unfavorable clinical outcomes due to their roles in immune suppression, the development of distant metastases, and local therapy resistance [1,2,3]. The TME is a complex system composed of various cells, including tumor-infiltrating immune cells, CAFs, and endothelial cells embedded in the extracellular matrix.

This study sought to identify novel CD8+ T cell homing markers by studying acute graft versus host disease (aGvHD), typically involving increased T cell homing to the skin and gut. FACS‐sorted skin‐homing (CD8β+/CLA+), gut‐homing (CD8β+/integrinβ7+), and reference (CD8β+/CLA‐/integrinβ7‐) T cells were compared in patients affected by cutaneous and/or gastrointestinal aGVHD.